U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H32N2.2C4H5O6
Molecular Weight 538.5858
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTOLINIUM TARTRATE

SMILES

O[C@H]([C@@H](O)C([O-])=O)C(O)=O.O[C@H]([C@@H](O)C([O-])=O)C(O)=O.C[N+]2(CCCCC[N+]1(C)CCCC1)CCCC2

InChI

InChIKey=HSMKTIKKPMTUQH-WBPXWQEISA-L
InChI=1S/C15H32N2.2C4H6O6/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17;2*5-1(3(7)8)2(6)4(9)10/h3-15H2,1-2H3;2*1-2,5-6H,(H,7,8)(H,9,10)/q+2;;/p-2/t;2*1-,2-/m.11/s1

HIDE SMILES / InChI
Molecular Formula C15H32N2
Molecular Weight 240.428
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves.

Originator

May & Baker
3
Curator's Comment: In 1952, Libman, Pain and Slack in the laboratories of May & Baker, London

Approval Year

1954
117
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ANSOLYSEN

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
80 mg 3 times / day multiple, intravenous
Dose: 80 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
Other AEs: Dizziness, Constipation...
Other AEs:
Dizziness
Constipation
Vomiting
Paralytic ileus (grade 5)
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
AEs

AEs

AESignificanceDosePopulation
Constipation
80 mg 3 times / day multiple, intravenous
Dose: 80 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
Dizziness
80 mg 3 times / day multiple, intravenous
Dose: 80 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
Vomiting
80 mg 3 times / day multiple, intravenous
Dose: 80 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
Paralytic ileus grade 5
80 mg 3 times / day multiple, intravenous
Dose: 80 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: 58 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13688462
Sourcing

Sourcing

Vendor/AggregatorIDURL
AAA Chemistry
AR-1B4870
ABI Chem
AC1L1L9T
ABI Chem
AC1Q28R1
Acros Organics
38802
BOC Sciences
52-62-0
ChemTik
CTK8D7628
Enamine
EN300-754676
Frontier Scientific Services
500054405
Kingston Chemistry
KST-1B3415
Lab Network
LN01349207
Molnova
M14862
MuseChem
M071777
NovoSeek
5850
Ryan Scientific
Clorgyline_HCl
Sigma Aldrich
R278084
Sigma Aldrich
R278084|ALDRICH
TargetMol
T1236
Tetrahedron
TS83657
TimTec
ST50411507
ZINC
ZINC000002041380
http://zinc15.docking.org/substances/ZINC000002041380
eMolecules
713499
mcule
MCULE-6392147155
https://mcule.com/MCULE-6392147155/
PubMed

PubMed

TitleDatePubMed
Upregulation of immunoreactive angiotensin II release and angiotensinogen mRNA expression by high-frequency preganglionic stimulation at the canine cardiac sympathetic ganglia.
2001 Jan 19
Short exposure of maturing, bone marrow-derived dendritic cells to norepinephrine: impact on kinetics of cytokine production and Th development.
2002 Aug
Chronic central infusion of orexin-A increases arterial pressure in rats.
2002 Mar 15
The altered balance between sympathetic nervous system and nitric oxide in salt hypertensive Dahl rats: ontogenetic and F2 hybrid studies.
2002 May
In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission.
2002 May 31
Human coagulation factor XII-related "new pressor protein": role of PACAP in its cardiovascular and sympathoadrenal effects.
2002 Oct
Release of acetylcholine by Die-Huang-Wan to enhance insulin secretion for lowering plasma glucose in Wistar rats.
2002 Sep 30
The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure.
2003 Nov 28
Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase.
2004 Jan
Role of bradykinin B2-receptor in the sympathoadrenal effects of 'new pressor protein' related to human blood coagulation factor XII fragment.
2004 Jun
Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats.
2004 May
Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms.
2005 Apr
Cardiovascular effects of noradrenaline microinjected into the dorsal periaqueductal gray area of unanaesthetized rats.
2005 Dec
Release of acetylcholine by Hon-Chi to raise insulin secretion in Wistar rats.
2006 Aug 14
Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats.
2006 Dec
Effects of chronic treatment with 7-nitroindazole in hyperthyroid rats.
2006 Nov
Pressor effects of noradrenaline injected into the lateral septal area of unanesthetized rats.
2006 Nov 29
Cardiovascular effects of carbachol microinjected into the bed nucleus of the stria terminalis of the rat brain.
2007 Apr 27
Vasorelaxant activity of some oxime derivatives.
2007 Dec 1
Total peripheral resistance responsiveness during the development of secondary renal hypertension in dogs.
2007 Mar
The participation of brain NO synthase in blood pressure control of adult spontaneously hypertensive rats.
2007 Mar
Cardiovascular effects of L-glutamate microinjection in the supraoptic nucleus of unanaesthetized rats.
2007 May
Angiotensin II-based hypertension and the sympathetic nervous system: the role of dose and increased dietary salt in rabbits.
2007 Sep
Cardiovascular responses to noradrenaline microinjection in the ventrolateral periaqueductal gray of unanesthetized rats.
2008 Feb 15
Neuronal source of plasma dopamine.
2008 Nov
Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa.
2009 Apr
The role of nitric oxide in the development of neurogenic pulmonary edema in spinal cord-injured rats: the effect of preventive interventions.
2009 Oct
Role of the sympathetic nervous system in Schlager genetically hypertensive mice.
2009 Oct
Enhanced responses to ganglion blockade do not reflect sympathetic nervous system contribution to angiotensin II-induced hypertension.
2009 Sep
Cardiovascular effects of noradrenaline microinjection into the medial part of the superior colliculus of unanesthetized rats.
2009 Sep 22
Role of sympathetic tone in BSO-induced hypertension in mice.
2010 Aug
Patents

Patents

US2016166555
2
US2016176822
2
US2016176873
2
US2016213586
2
US2016235675
2
US2016235846
2
US2016250238
2

Sample Use Guides

In Vivo Use Guide
intramuscularly: 1 to 2 0.25-mg ampoules Ansolysen must be used with caution. The initial dose is from 20-40 mg., taken 15 to 20 minutes before each meal and at bedtime, to ensure an even digestive absorption. Each dose is increased by 20-40 mg. four times a day at intervals of five to seven days until the desired hvpotensive effect is obtained. The maintenance dose varies generally between 160 and 800 mg. a day.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:09:32 GMT 2023
Edited
by admin
on Fri Dec 15 15:09:32 GMT 2023
Record UNII
953357GACY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTOLINIUM TARTRATE
MI   ORANGE BOOK  
Common Name English
ANSOLYSEN
Brand Name English
PENTOLINIUM TARTRATE [MI]
Common Name English
PENTOLONIUM TARTRATE [MART.]
Common Name English
Pentolonium tartrate [WHO-DD]
Common Name English
pentolonium tartrate [INN]
Common Name English
NSC-759890
Code English
PENTOLONIUM TARTRATE
INN   MART.   WHO-DD  
INN  
Official Name English
PYRROLIDINIUM 1,1'-(1,5-PENTANEDIYL)BIS-(1-METHYL-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE
Common Name English
PENTOLINIUM TARTRATE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C270
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
NCI_THESAURUS C66886
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
Code System Code Type Description
NSC
759890
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
FDA UNII
953357GACY
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
PUBCHEM
5849
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
EVMPD
SUB09700MIG
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
MERCK INDEX
m8515
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5045542
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
NCI_THESAURUS
C66345
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
DRUG BANK
DBSALT000236
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
MESH
D010425
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
CHEBI
55326
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
CAS
52-62-0
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
SMS_ID
100000082536
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-146-7
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL1271
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
INN
330
Created by admin on Fri Dec 15 15:09:32 GMT 2023 , Edited by admin on Fri Dec 15 15:09:32 GMT 2023
PRIMARY
Related Record Type Details
Structure of TARTARIC ACID
PARENT -> SALT/SOLVATE
Structure of PENTOLINIUM
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PENTOLINIUM
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966